ACCEL-CANDESARTAN TABLET

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

CANDESARTAN CILEXETIL

Disponibbli minn:

ACCEL PHARMA INC

Kodiċi ATC:

C09CA06

INN (Isem Internazzjonali):

CANDESARTAN

Dożaġġ:

8MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

CANDESARTAN CILEXETIL 8MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

100

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0135220002; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED POST MARKET

Data ta 'l-awtorizzazzjoni:

2020-03-05

Karatteristiċi tal-prodott

______________________________________________________________________________
_Accel-Candesartan Product Monograph_
_ Page 1 of 34_
PRODUCT MONOGRAPH
PR
ACCEL-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg tablets
Angiotensin II AT
1
Receptor Blocker
Accel Pharma Inc.
99 Place Frontenac,
Point-Claire, Quebec
H9R 4Z7
_www.accelpharma.com _
Submission Control Number: 204353
Date of Preparation:
May 8, 2017
Product Monograph
Pg. 1
______________________________________________________________________________
_Accel-Candesartan Product Monograph_
_ Page 2 of 34_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
..............................................................................................................
4
WARNINGS AND PRECAUTIONS
.............................................................................................
4
ADVERSE REACTIONS
...............................................................................................................
8
DRUG INTERACTIONS
.............................................................................................................
13
DOSAGE AND ADMINISTRATION
.........................................................................................
15
OVERDOSAGE
...........................................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................
18
STORAGE AND STABILITY
.....................................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................ 20